P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma
Gullu Gorgun,Kristen Cowens,Steven Paula,Mehmet Kemal Samur,Hiroto Ohguchi,Ahaana Singh,Randie E White,Giada Bianchi,Rikio Suzuki,Shohei Kikuchi,Takeshi Harada,Naoya Mimura,Yu-Tzu Tai,Teru Hideshima,Jacob P. Laubach,Noopur Raje,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +18 more
TL;DR: PD-1/PD-L1 blockade overcame BMSC-induced tumor cell growth in both patient MM cells and MM cell lines and significantly induced cytotoxicity in autologous cocultures of immune effector cells with MM cells.
Journal ArticleDOI
Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells.
Douglas W. McMillin,Jake Delmore,Joseph Negri,Patrick Hayden,Nicholas Mitsiades,Paul G. Richardson,Robert L. Schlossman,Nikhil C. Munshi,Kenneth C. Anderson,Constantine S. Mitsiades +9 more
TL;DR: Preclinical studies on the anti-MM activity of the selective CDK1/2 small molecule inhibitor NVP-LCQ195/AT9311 show functional inhibition of proteins involved in cell cycle regulation remains an attractive approach for the treatment of multiple myeloma.
Journal ArticleDOI
Compartment-Specific Bioluminescence Imaging (CS-BLI): A High-Throughput Approach To Identify Novel Anti-Neoplastic Therapies That Overcome the Protection of Stromal Cells.
Douglas W. McMillin,Joseph Negri,Patrick Hayden,Ellen Weisberg,Steffen Klippel,Robert L. Schlossman,Nikhil C. Munshi,Nicholas Mitsiades,Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades +10 more
TL;DR: CS-BLI is able to overcome the key limitations that have precluded the establishment of high-throughput screening for testing new drugs in tumor-stroma co-cultures and provides sensitive detection of viable MM cells, both in the presence and absence of BMSCs.
Journal ArticleDOI
CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis
Yu-Tzu Tai,Yosef Landesman,Chirag Acharya,Mike Y Zhong,Yolanda Calle,Michele Cea,Yiguo Hu,Antonia Cagnetta,Daniel Tannenbaum,Michelle C. Chen,Aditya Munshi,William Senapedis,Jean-Richard Saint-Martin,Trinayan Kashyap,Haoqiang Ying,Dilara McCauley,Sharon Shacham,Michael Kauffman,Yumei Gu,Lizi Wu,Stephen Schey,Andrew L. Kung,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +24 more
TL;DR: CRM1 is identified as a promising novel target in MM, strongly supporting clinical development of SINE CRM1 antagonists to inhibit both MM cell growth and related bone disease.
Journal ArticleDOI
Pooled Treatment Analysis of Pediatric Patients with Defibrotide for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Multi-Organ Dysfunction Following Hematopoietic Stem Cell Transplant
Nancy A. Kernan,Stephan A. Grupp,Kamalika Banerjee,Alison L. Hannah,Robin Hume,Bijan Nejadnik,Paul G. Richardson +6 more
TL;DR: This data indicates that single-cell transplants with a single single excision procedure are more beneficial than double-bypass surgery for at least some of the mechanisms leading to cell reprograming.